Physician profile
Abraham Parail
NPI 1073551909
$8,886.54
in general payments reported to CMS, 2019-2025
23 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $275 · 2021: $169 · 2022: $1,507 · 2023: $843 · 2024: $1,081 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Consulting Fee: $1,875 · Travel and Lodging: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.74 |
| Consulting Fee | $1,875.00 |
| Travel and Lodging | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,121.30 | 2022-2025 | Avvigo Guidance System, Watchman Flx, Opticross |
| Abbott Laboratories | $1,173.51 | 2022-2023 | Portico, Amplatzer Amulet |
| W. L. Gore & Associates, INC. | $1,119.63 | 2019-2025 | Gore Viabahn Endoprosthesis With Heparin |
| Abiomed | $901.73 | 2019-2022 | |
| Edwards Lifesciences Corporation | $793.03 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Pascal |
| Medtronic, INC. | $765.61 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Amgen INC. | $235.17 | 2022-2024 | Repatha |
| Cardiovascular Systems INC. | $133.43 | 2020-2022 | |
| Medtronic Vascular, INC. | $120.31 | 2019-2020 | |
| Penumbra, INC. | $96.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $92.08 | 2023-2024 | |
| Novo Nordisk INC | $57.29 | 2024-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2023 | Eliquis, Camzyos |
| Biosense Webster, INC. | $38.66 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.20 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36.52 | 2022-2023 | |
| Cardiva Medical, INC. | $21.22 | 2024 | Savvywire |
| Pfizer INC. | $20.57 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.15 | 2024 | Lifevest |
| Biotronik INC. | $17.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.36 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $15.08 | 2020 | |
| Teleflex LLC | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Parail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.